What is the role of recombinant brain natriuretic peptide (BNP) in the evaluation of congestive heart failure (CHF)?

Updated: Jan 08, 2018
  • Author: Donald Schreiber, MD, CM; Chief Editor: Erik D Schraga, MD  more...
  • Print


Recombinant brain natriuretic peptide (BNP), also known as nesiritide, has been studied as a therapeutic adjunct in acute decompensated congestive heart failure (CHF). [10, 11, 12, 13, 14, 15] Nesiritide (Natrecor, Scios Inc; Fremont, Calif) received a US Food and Drug Administration (FDA)–approved indication for the treatment of acute decompensated heart failure with dyspnea in 2001.

The treatment of CHF with recombinant BNP is beyond the scope of this article. However, the clinician must be aware that nesiritide is a BNP measured by the BNP assay. Therefore, the measurement of BNP is not indicated in patients who are receiving nesiritide. If BNP is used as a diagnostic marker to rule in CHF, the level must be determined before nesiritide therapy is started. NT-proBNP is not therapeutically active, and it does not affect the measurement of NT-proBNP levels.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!